Journals / Turkish Journal of Gastroenterology / 2016 / Cilt: 27 - Sayı: 2

Prevalence of QT interval prolongation in inflammatory bowel disease

Pages
136–142
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Our study demonstrates that patients with IBD are at a higher risk of developing QTc interval prolongation

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/Aims: There is growing evidence linking various cardiac complications with inflammatory bowel disease (IBD).
📊
Key Findings & Data:Our objective was to evaluate the prevalence of abnormal QT interval prolongation (defined by a QT interval of >450 ms in men and >460 ms in women) in an IBD population.
💡
Conclusion & Impact:Conclusion: Our study demonstrates that patients with IBD are at a higher risk of developing QTc interval prolongation
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Background/Aims: There is growing evidence linking various cardiac complications with inflammatory bowel disease (IBD). Electrolyte abnormalities, chronic inflammation, and medication use (such as Infliximab) that are associated with IBD are all independent risk factors for QT interval prolongation. Given that malignant ventricular arrhythmias are associated with QT interval prolongation, it is important to risk stratify this subset of patients. Our objective was to evaluate the prevalence of abnormal QT interval prolongation (defined by a QT interval of >450 ms in men and >460 ms in women) in an IBD population. Materials and Methods: A retrospective chart review of patients with IBD from the Metro Hospital database was performed. Patients' demographic characteristics and laboratory data were abstracted. "RR" and "QT" intervals were measured from the last available electrocardiogram, and corrected QT (QTc) interval was calculated from lead II using Bazett's formula. Results: Of 142 eligible patients, 42.3% (n=22/52) of males and 48.9% (n=44/90) of females had a prolonged QTc interval. Patients with IBD having a prolonged QTc interval had a higher body mass index than those with a normal QTc interval (29.7±6.9 vs. 26.2±5.9, p=0.005). Conclusion: Our study demonstrates that patients with IBD are at a higher risk of developing QTc interval prolongation

🔖

Cite This Article

PATTANSHETTY, D. J., GAJUAPALLI, R. D., ANNA, K., BIYYANI, R. S. S. (2016). Prevalence of QT interval prolongation in inflammatory bowel disease. Turkish Journal of Gastroenterology, Cilt: 27 - Sayı: 2, 136–142. https://ajindex.com/articles/411309

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (3)

  1. Bednar MM, Harrigan EP, Anziano RJ, Camm AJ, Ruskin JN. The QT interval. Prog Cardiovasc Dis 2001; 43: 11-45. [CrossRef] Fayssoil A, Issi J, Guerbaa M, Raynaud JC, Heroquelle V. Torsades de pointes induced by citalopram and amiodarone. Ann Cardiol Angeiol (Paris) 2011; 60: 165-8. [CrossRef] Bernstein CN, Blanchard JF, Rawsthorne P, Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease: a popula- tion-based study. Am J Gastroenterol 2001; 96: 1116-22. [CrossRef] Priori SG, Schwartz PJ, Napolitano C, et al. Risk stratification in the long-QT syndrome. N Engl J Med 2003; 348: 1866-74. [CrossRef] Bharati S, Dreifus L, Bucheleres G, et al. The Conduction System in Patients with a Prolonged QT Interval. J Am Coll Cardiol 1985; 6: 1110-9. [CrossRef] Ricart E, Panaccione R, Loftus EV Jr, et al. Autoimmune disorders and extraintestinal manifestations in first-degree familial and sporadic inflammatory bowel disease: a case-control study. In- flamm Bowel Dis 2004; 10: 207-14. [CrossRef] Bernstein CN, Wajda A, Blanchard JF. The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population- based study. Gastroenterology 2005; 129: 827-36. [CrossRef] Mendoza JL, Lana R, Taxonera C, Alba C, Izquierdo S, Diaz-Rubio M. Extraintestinal manifestations in inflammatory bowel disease: differences between Crohn's disease and ulcerative colitis. Med Clin (Barc) 2005; 125: 297-300.
  2. Iizuka B, Yamagishi N, Honma N, Hayashi N. Cardiovascular dis- ease associated with ulcerative colitis. Nippon Rinsho 1999; 57: 2540-5.
  3. Pattanshetty DJ, Anna K, Biyyani RSS, Maxwell J. 'Inflammatory Bowel 'Cardiac' Disease: Prevalence of Atrial Fibrillation in Inflam- matory Bowel Disease (IBD)'. Heart Rhythm 2011; 8: S376-7. Sappati Biyyani RS, Fahmy NM, Baum E, Nelson KM, King JF. In- flammatory bowel disease and coronary artery disease. Indian J Gastroenterol 2009; 28: 28-30. [CrossRef] Sİrensen HT, Fonager KM. Myocarditis and inflammatory bowel disease. A 16-year Danish nationwide cohort study. Dan Med Bull 1997; 44: 442-4. Koutroubakis IE. Role of thrombotic vascular risk factors in inflam- matory bowel disease. Dig Dis 2000; 18: 161-7. [CrossRef] Caviglia R, Boskoski I, Cicala M. Long-term treatment with inflix- imab in inflammatory bowel disease: safety and tolerability is- sues. Expert Opin Drug Saf 2008; 7: 617-32. [CrossRef] DI Franco M, Paradiso M, Ceccarelli F, et al. Biological drug treatment of rheumatoid arthritis and spondyloarthri